Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patientsYu Sawada, Tetsuya Nakatsura, Shinichiro Takahashi et al.|OncoImmunology|2016Cited by 178
Perioperative plasma glypican-3 level may enable prediction of the risk of recurrence after surgery in patients with stage I hepatocellular carcinomaKazuya Ofuji, Tetsuya Nakatsura, Keigo Saito et al.|Oncotarget|2016Cited by 28
Abstract CT115: Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patientsYu Sawada, Tetsuya Nakatsura, Toshiaki Yoshikawa et al.|Cancer Research|2015Cited by 0
Abstract B73: Proof of glypican-3 (GPC3) peptide specific CTLs infiltrating into tumor tissue derived from advanced HCC patient vaccinated with GPC3 peptide.Toshiaki Yoshikawa, Tetsuya Nakatsura, Mayuko Sakai et al.|Cancer Research|2013Cited by 0